Latest Consumer Health News

Page 1 of 4
Hydration Pharmaceuticals sharply reduced Hydralyte LLC’s US operating loss in the September quarter after cutting costs and refocusing marketing. But weaker September trading, stock-outs, limited cash and an ununderwritten entitlement offer leave the turnaround unfinished.
Victor Sage
Victor Sage
11 Nov 2026
Starpharma is targeting a December start for first-in-human testing of its lead DEP HER2-Lu radiopharmaceutical, subject to ethics approval, as it shifts decisively toward targeted oncology. The company also outlined stronger funding, majority ownership of Petalion’s FAP program and a proposed Chair transition at its 2026 AGM.
Ada Torres
Ada Torres
6 Nov 2026
Kimberly-Clark delivered stronger adjusted earnings from continuing operations in the third quarter, but organic sales and adjusted operating profit weakened as China disruption, pricing pressure and costs weighed on results. The company reaffirmed its 2026 outlook while beginning life as a larger consumer-health group after completing its Kenvue acquisition.
Victor Sage
Victor Sage
5 Nov 2026
Kimberly-Clark has completed its acquisition of Kenvue, leaving Kenvue shareholders with a mix of Kimberly-Clark stock and cash while ending Kenvue’s life as a standalone listed company. The transaction also transfers Kenvue’s debt and corporate obligations into a new wholly owned subsidiary.
Victor Sage
Victor Sage
3 Nov 2026
Kimberly-Clark has completed its acquisition of Kenvue, issuing about 281.1 million shares and taking on an integration programme expected to cost US$3.1 billion before tax. The combined group is targeting US$2.1 billion in annual run-rate synergies by reshaping its brands, segments and operating model.
Victor Sage
Victor Sage
3 Nov 2026
EZZ Life Science cut its quarterly operating cash outflow sharply despite a 37.7% drop in customer receipts, as weaker Chinese e-commerce sales continued to weigh. EAORON skincare growth and a $9.16 million cash balance offer some support, but distributor collections and potential product returns remain unresolved.
Victor Sage
Victor Sage
30 Oct 2026
Hydralyte LLC recorded its first monthly operating profit in August, while a major cost reset cut its quarterly operating loss to US$66,900. But revenue fell 21.9%, cash narrowed to US$173,400 and the company is seeking up to A$1.4 million through a rights issue.
Victor Sage
Victor Sage
30 Oct 2026
Nutritional Growth Solutions has cut quarterly net operating cash outflow by 54% while completing its Sprout Organic acquisition just after quarter end. The enlarged group starts with US$1.613 million in cash, no borrowings and a substantially larger share base.
Victor Sage
Victor Sage
30 Oct 2026
Me Today says more than 80% of its Series 1 warrants have been exercised, delivering $2.31 million of new capital as the nutraceuticals company forecasts stronger first-half FY27 revenue. FY26 gross revenue rose 36% to $7.96 million while the EBITDA loss narrowed substantially.
Victor Sage
Victor Sage
29 Oct 2026
Hydration Pharmaceuticals is asking eligible shareholders for up to A$1.43 million in fresh capital as it funds the next phase of its turnaround. The non-renounceable offer comes with free options, but is neither underwritten nor subject to a minimum subscription.
Ada Torres
Ada Torres
23 Oct 2026
Firebrick Pharma is escalating Nasodine’s US push from online sales into retail pharmacies while its September-quarter cash balance fell to A$875,000. The company reported a A$398,000 operating cash outflow and estimated 2.2 quarters of funding at the current rate.
Victor Sage
Victor Sage
23 Oct 2026
Firebrick Pharma has approved a phased push into US retail pharmacies after Nasodine online sales grew by more than 200% in FY26. Up to six regional pharmacy groups representing about 700 stores have expressed strong interest in early orders, although no binding orders have been disclosed.
Ada Torres
Ada Torres
29 Sept 2026

Browse the archive

Full archive